Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions

American Journal of Clinical Pathology

Volumn 115, Issue 4, 2001, Pages 517-524

  Davidson, Ben ^a   Goldberg, Iris ^d   Berner, Aasmund ^a   Nesland, Jahn M ^a   Givant Horwitz, Vered ^c   Bryne, Magne ^a,b   Risberg, Bjørn ^a   Kristensen, Gunnar B ^a   Tropé, Claes G ^a   Kopolovic, Juri ^d   Reich, Reuven ^c,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

Membrane type matrix metalloproteinases; Messenger RNA in situ hybridization; Ovarian carcinoma; Polymerase chain reaction; Serous effusions

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; MESSENGER RNA; STROMELYSIN;

ARTICLE; CARCINOMA CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; OVARY CARCINOMA; PERITONEUM EXUDATE; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL;

ASCITIC FLUID; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEROUS MEMBRANE;

EID: 17744394053     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/B1YX-L8DB-TGY1-7905     Document Type: Article

References (38)

1. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 1991;51(suppl):5054s-5059s.
2. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260-1270.
3. Seiki M. Membrane-type matrix metalloproteinases. APMIS. 1999;107:137-143.
4. Polette M, Birembaut P. Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol. 1998;30:1195-1202.
5. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature. 1994;370:61-65.
6. Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human metalloproteinase with a potential transmembrane segment. Eur J Biochem. 1995; 231:602-608.
7. Takino T, Sato H, Shinagawa A, et al. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library: MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem. 1995;270:23013-23020.
8. Puente XS, Pendas AM, Llano E, et al. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res. 1996;56:944-949.
9. Llano E, Pendas AM, Freije JP, et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A overexpressed in brain tumors. Cancer Res. 1999;59:2570-2576.
10. Velasco S, Cal S, Merlos-Suarez A, et al. Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res. 2000;60:877-882.
11. Sato H, Okada Y, Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Thromb Haemost. 1997;78:497-500.
12. Murphy M, Stanton H, Cowell S, et al. Mechanisms for pro matrix metalloproteinase activation. APMIS. 1999;107:38-44.
13. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64.
14. Hoskins WJ. Prospective on ovarian cancer: why prevent? J Cell Biochem Suppl. 1995;23:189-199.
15. Stack MS, Ellerbroek SM, Fishman DA. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int J Oncol. 1998;12:569-576.
16. Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis. 1996;16:150-159.
17. Afzal S, Lalani EN, Poulsom R, et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol. 1998;29:155-165.
18. Bedrossian CWM. Malignant Effusions: A Multimodal Approach to Cytologic Diagnosis. New-York, NY: Igaku-Shoin; 1994.
19. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies: evaluation of five epithelial markers. Virchows Arch. 1999;435:43-49.
20. Young RH, Clement PB, Scully RE. Surface epithelial-stromal tumors of the ovary. In: Sternberg SS, ed. Diagnostic Surgical Pathology, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:2319-2382.
21. Davidson B, Goldberg I, Kopolovic J, et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma: a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol. 1999;73:372-382.
22. Tokuraku M, Sato H, Murakami S, et al. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastases. Int J Cancer. 1995;64:355-359.
23. Imamura T, Ohshio G, Mise M, et al. Expression of membrane-type matrix metalloproteinase-1 in human pancreatic adenocarcinomas. J Cancer Res Clin Oncol. 1998;124:65-72.
24. Kanayama H, Yokota K, Kurokawa Y, et al. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer. 1998;82:1359-1366.
25. Okada A, Bellocq J-P, Rouyer N, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA. 1995;92:2730-2734.
26. Harada T, Arii S, Mise M, et al. Membrane-type matrix metalloproteinase-1 (MT1-MMP) gene is overexpressed in highly invasive hepatocellular carcinomas. J Hepatol. 1998;28:231-239.
27. Gilles C, Polette M, Piette J, et al. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer. 1996;65:209-213.
28. Ohtani H, Motohashi H, Sato H, et al. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy. Int J Cancer. 1996;68:565-570.
29. Polette M, Nawrocki B, Gilles C, et al. MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch. 1996;428:29-35.
30. Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res. 1999;59;467-473.
31. Ueno H, Nakamura H, Inoue M, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res. 1997;57:2055-2060.
32. Kitagawa Y, Kunimi K, Ito H, et al. Expression and tissue localization of membrane-types 1,2, and 3 matrix metalloproteinases in human urothelial carcinomas. J Urol. 1998;160:1540-1545.
33. Chenard MP, Lutz Y, Mechine-Neuville A, et al. Presence of high levels of MT1-MMP protein in fibroblastic cells of human invasive carcinomas. Int J Cancer. 1999;82:208-212.
34. Curtin JP, Malik R, Venkatraman ES, et al. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997; 64:9-12.
35. Makar AP, Baekelandt M, Tropé CG, et al. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995;56:175-180.
36. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994;10:31-46.
37. Davidson B, Berner A, Nesland JM, et al. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and sialyl Tn antigen expression in effusions. Hum Pathol. 2000;31:1081-1087.
38. Davidson B, Berner A, Nesland JM, et al. E-cadherin and alpha-, beta- and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol. 2000;192:460-469.